Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8NDH3

UPID:
PEPL1_HUMAN

ALTERNATIVE NAMES:
Aminopeptidase-like 1

ALTERNATIVE UPACC:
Q8NDH3; A6NGZ0; B4DMW7; B7ZBN0; E9PN47; G5EA34; Q53G37; Q5W083; Q8TF28; Q8WUI2; Q9H1T6; Q9HAI5

BACKGROUND:
The enzyme Probable aminopeptidase NPEPL1, alternatively named Aminopeptidase-like 1, plays a pivotal role in the initial steps of protein degradation. It is believed to specifically target and remove N-terminal amino acids from peptides, a process essential for protein maturation and turnover.

THERAPEUTIC SIGNIFICANCE:
Investigating Probable aminopeptidase NPEPL1's enzymatic activities offers a promising pathway for uncovering new therapeutic avenues. As it is involved in critical protein processing pathways, targeting this enzyme could lead to innovative treatments for diseases where protein accumulation or misprocessing is a factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.